Immunome
IMNM
202 hedge funds and large institutions have $2.54B invested in Immunome in 2026 Q1 according to their latest regulatory filings, with 51 funds opening new positions, 74 increasing their positions, 47 reducing their positions, and 27 closing their positions.
89% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 27
57% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 47
11% more funds holding
Funds holding: 182 → 202 (+20)
0% more capital invested
Capital invested by funds: $2.54B → $2.54B (+$4.34M)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
25.86% less ownership
Funds ownership: 128.99% → 103.13% (-26%)
77% less call options, than puts
Call options by funds: $7.08M | Put options by funds: $30.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$84.5M |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$65.5M |
| 3 |
State Street
Boston,
Massachusetts
|
+$34.1M |
| 4 |
Morgan Stanley
New York
|
+$25.2M |
| 5 |
BNP Paribas Asset Management
Paris,
France
|
+$20.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$151M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$61.3M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$37M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$26.2M |
| 5 |
ES
Enavate Sciences
Menlo Park,
California
|
-$25.7M |
IMNM Hedge Fund Activity: Q1 2026 in Review
202 of the 8,191 institutional investors tracked by Wall St. Rank reported a position in Immunome (IMNM) for Q1 2026, worth a combined $2.54B — up 0.17% from $2.54B a quarter earlier.
Buyers outnumbered sellers: 51 funds opened new IMNM positions and 27 closed out — a net gain of 24 holders — while 74 added to existing stakes and 47 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $84.5M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $151M sold.
- 202 institutional investors held Immunome (IMNM) as of Q1 2026, up from 182 in Q4 2025.
- Funds reported $2.54B of Immunome stock for Q1 2026, up 0.17% quarter-over-quarter.
- 51 funds opened new Immunome positions in Q1 2026 and 27 closed out, a net change of +24 holders.
- The largest Immunome buyer in Q1 2026 was Wellington Management Group, an estimated $84.5M added.
- The largest Immunome seller in Q1 2026 was Point72 Asset Management, an estimated $151M sold.
Based on aggregated 13F filings for Q1 2026.